MOTS-c vs MK-677

MOTS-c and MK-677 represent two distinct classes of research peptides with overlapping but divergent applications. MOTS-c is a mitochondrial-derived peptide that acts as a metabolic regulator, primarily studied in preclinical models for its effects on insulin sensitivity, exercise capacity, and obesity. In contrast, MK-677 is a non-peptide ghrelin receptor agonist that stimulates growth hormone secretion and has been evaluated in multiple human clinical trials for conditions like GH deficiency and muscle wasting. While both are explored in anti-aging research, their mechanisms, evidence bases, and safety profiles differ substantially. This overview highlights these key distinctions to aid researchers in selecting the appropriate peptide for their specific experimental goals.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome, discovered in 2015 by Lee et al. at the University of Southern California. It functions primarily through AMPK activation, influencing metabolic pathways such as glucose uptake and fatty acid oxidation. In preclinical mouse models, MOTS-c has been shown to prevent diet-induced obesity and insulin resistance, and to enhance exercise endurance—old mice treated with MOTS-c ran twice as long on treadmill tests compared to controls. These findings position MOTS-c as a potential exercise mimetic and anti-obesity agent. A modified analog, CB4211, demonstrated good tolerability in a Phase 1 human trial, but no clinical trials of native MOTS-c have been completed. Thus, the evidence base remains largely preclinical, with human data limited to safety assessments of the analog.

MK-677 (Ibutamoren) is a potent, orally active, non-peptide agonist of the ghrelin receptor (GHS-R1a), which stimulates growth hormone (GH) secretion from the pituitary. Unlike injectable GH secretagogues such as GHRP-6 or Ipamorelin, MK-677 is administered orally and maintains elevated GH and insulin-like growth factor 1 (IGF-1) levels for up to 24 hours. It has been investigated in several human clinical trials for conditions including growth hormone deficiency, muscle wasting in the elderly, bone density improvement, and sleep quality enhancement. Despite these studies, MK-677 is not FDA-approved for any indication. The evidence base is robust, with multiple randomized controlled trials demonstrating its efficacy in increasing lean body mass and improving sleep, but it also carries metabolic risks such as elevated fasting glucose and reduced insulin sensitivity, which are dose-dependent.

Both MOTS-c and MK-677 are studied in the context of anti-aging, though through different mechanisms. MOTS-c is primarily researched for metabolic health, including improvements in insulin sensitivity, glucose metabolism, and exercise capacity, which are relevant to age-related metabolic decline. MK-677 is additionally investigated for body composition (increasing lean body mass) and sleep quality, due to its GH-releasing effects. While MOTS-c's anti-aging applications are rooted in mitochondrial and metabolic regulation, MK-677's are linked to the GH/IGF-1 axis, which influences tissue repair and muscle maintenance. Researchers should note that MOTS-c's evidence is preclinical, whereas MK-677 has clinical data, making MK-677 more directly translatable to human physiology studies.

MOTS-c has shown no adverse effects in preclinical animal studies, but human tolerability of native MOTS-c remains unknown due to the absence of completed human trials. The modified analog CB4211 was well-tolerated in a Phase 1 trial, suggesting potential safety, but direct data on native MOTS-c are lacking. In contrast, MK-677 has a well-documented safety profile from clinical trials. Common side effects include increased appetite (due to ghrelin agonism), water retention or mild edema, and transient muscle pain. Metabolic concerns are significant: MK-677 can elevate fasting blood glucose and reduce insulin sensitivity in a dose-dependent manner, which is particularly relevant for diabetic or pre-diabetic populations. Fatigue and lethargy have also been reported. Researchers must weigh these risks against the more limited safety data for MOTS-c.